TRASTUZUMAB DUOCARMAZINE
UNII XCR2BZ80N7

Substance Identification & Data

This profile provides standardized clinical and technical data for Trastuzumab Duocarmazine, uniquely identified by the FDA Unique Ingredient Identifier (UNII) XCR2BZ80N7.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1642152-40-6 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

XCR2BZ80N7

CAS Registry Number

1642152-40-6

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TRASTUZUMAB DUOCARMAZINE

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C118674

National Cancer Institute reference terminology for clinical and research data.

INN ID

10273

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

FG-131

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Trastuzumab Duocarmazine. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

TRASTUZUMAB DUOCARMAZINE

Common Names & Synonyms

TRASTUZUMAB DUOCARMAZINE [INN]

TRASTUZUMAB DUOCARMAZINE [USAN]

TRASTUZUMAB DUOCARMAZINE [WHO-DD]

Systematic Nomenclature

IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MUS MUSCULUS MONOCLONAL SYD977 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL SYD977 LIGHT CHAIN, DIMER, THIOETHER WITH N-((2-(2-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)ETHOXY)ETHOXY)CARBONYL)-L-VALYL-N5-(AMINOCARBONYL)-N-(4-(7-((((1S)-1-(CHLOROMETHYL)-2,3-DIHYDRO-3-((6-((4-HYDROXYBENZOYL)AMINO)IMIDAZO(1,2-A)PYRIDIN-2-YL)CARBONYL)-9-METHYL-1H-BENZ(E)INDOL-5-YL)OXY)CARBONYL)-12-HYDROXY-4-METHYL-3-OXO-2,10-DIOXA-4,7-DIAZADODEC-1-YL)PHENYL)-L-ORNITHINAMIDE

SYS

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185CERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY CONJUGATED TO THE PRO-DRUG SECO-DUOCARMYCINHYDROXYBENZAMIDE- AZAINDOLE (SECO-DUBA)GAMMA1 HEAVY CHAIN (1-449) (HUMANIZED VH (HOMO SAPIENS (IGHV3-66-*01 (81.60%) -(IGHD)-IGHJ6*01) (8.8.13) (1-120) -HOMO SAPIENS IGHG1*01, G1M17, NG1M1 (CH1 (121-218), HINGE (219-233),CH2 (234-343), CH3 D12>E (359), L14>M (361) (344-448), CHS K>DEL (449)) (121-449)), (223-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1-214) (HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-39*01 (86.30%) -IGKJ1*01) (6.3.9) (1'-107') -HOMO SAPIENS IGKC*01, KM3 (108'-214')) DIMER (229-229:232-232)-BISDISULFIDE, CONJUGATED ON AN AVERAGE OF 2 OR 4 CYSTEINES, TO SECO-DUBA VIA THE CLEAVABLE LINKER N-(2-(2- MALEIMIDOETHOXY)ETHOXYCARBONYL)-L-VALYL-L-CITRULLINYLP- AMINOBENZYLOXYCARBONYL-N-(2-(2-HYDROXYETHOXY)ETHYL)- N-(2-(METHYLAMINO)ETHYL)CARBAMOYL

SYS